- Home
- PSTV
as 05-20-2024 4:00pm EST
$.
-
$.
-.%
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focuses on the discovery, development, and delivery of complex treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 9.4M | IPO Year: | N/A |
| Target Price: | $8.00 | AVG Volume (30 days): | 74.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.97 - $4.45 | Next Earning Date: | 05-15-2024 |
| Revenue: | $6,084,000 | Revenue Growth: | 733.42% |
| Revenue Growth (this year): | 5.54% | Revenue Growth (next year): | -43.61% |
Share on Social Networks:
Stock Insider Trading Activity of PLUS THERAPEUTICS Inc. (PSTV)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sims Andrew John Hugh MacIntyre | PSTV | Chief Financial Officer | May 8 '24 | Buy | $2.04 | 4,902 | $10,000.08 | 5,717 | SEC Form 4 |
| Petersen Greg | PSTV | Director | May 8 '24 | Buy | $2.04 | 12,255 | $25,000.20 | 36,421 | SEC Form 4 |
| Clowes Howard | PSTV | Director | May 8 '24 | Buy | $2.04 | 9,804 | $20,000.16 | 21,497 | SEC Form 4 |
| Hawkins Richard J | PSTV | Director | May 8 '24 | Buy | $2.04 | 4,902 | $10,000.08 | 4,903 | SEC Form 4 |
| HEDRICK MARC H | PSTV | Chief Executive Officer | Nov 20 '23 | Sell | $1.96 | 2,068 | $4,052.66 | 170 | SEC Form 4 |
| Lenk Robert P | PSTV | Director | Nov 15 '23 | Buy | $1.77 | 1,000 | $1,770.00 | 24,160 | SEC Form 4 |
| Lenk Robert P | PSTV | Director | Nov 15 '23 | Buy | $1.95 | 1,000 | $1,950.00 | 25,160 | SEC Form 4 |
| Lenk Robert P | PSTV | Director | Nov 8 '23 | Buy | $1.65 | 5,000 | $8,250.00 | 12,961 | SEC Form 4 |
| Lenk Robert P | PSTV | Director | Nov 8 '23 | Buy | $1.59 | 4,199 | $6,676.41 | 17,160 | SEC Form 4 |
Latest PLUS THERAPEUTICS Inc. News
PSTV Breaking Stock News: Dive into PSTV Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Plus Therapeutics Announces New Employment Inducement Grants
GuruFocus.com
5 days ago
Plus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...
GlobeNewswire
5 days ago
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
7 days ago
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
GlobeNewswire
11 days ago
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
GlobeNewswire
12 days ago
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
GlobeNewswire
14 days ago
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
Benzinga
a month ago